Your Messages Inbox
Your Article Summary
See Latest ArticlesAllos Therapeutics' FOLOTYN(TM) First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
Allos Therapeutics, 09/28/09
Allos Therapeutics, Inc. announced that last night the U.S. Food and Drug Administration granted accelerated approval for FOLOTYNTM for use as a single agent for the treatment of patients with relapsed or refractory peripheral T–cell lymphoma. FOLOTYN is the first and only drug approved by the FDA for this indication and represents a new treatment option for patients with relapsed or refractory PTCL.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor